Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Hum Cell. 2020 Jul;33(3):877-885. doi: 10.1007/s13577-020-00354-6. Epub 2020 Apr 9.
Synovial sarcoma is a rare malignancy of mesenchymal origin, characterized by a chromosomal translocation, t(X;18) (p11.2;q11.2). Wide surgical resection with radiation and cytotoxic chemotherapy is established as a standard treatment; however synovial sarcoma remains a high-grade sarcoma with poor prognosis, and novel anti-cancer agents and immunological approaches are currently being developed. The patient-derived cell line is a critical tool for basic and pre-clinical research. However, only a few patient-derived synovial sarcoma cell lines are publicly available from cell banks. Thus, the aim of this study was to establish and characterize a novel cell line for synovial sarcoma. Using a surgically resected tumor tissue from a 48-year-old female patient, we successfully established a cell line, named NCC-SS3-C1. NCC-SS3-C1 cells harbor an SS18-SSX1 fusion gene and exhibit moderate growth, spheroid formation, and invasion. We examined a range of proliferation-inhibiting effects of small molecule anti-cancer compounds, including FDA-approved anti-cancer drugs, using NCC-SS3-C1 cells, and identified anti-cancer drugs which inhibited the proliferation of NCC-SS3-C1 cells at the low concentration. We concluded that NCC-SS3-C1 would be a useful tool for basic and pre-clinical synovial sarcoma research.
滑膜肉瘤是一种罕见的间叶来源恶性肿瘤，其特征在于染色体易位 t(X;18)(p11.2;q11.2)。广泛的手术切除联合放疗和细胞毒性化疗是既定的标准治疗方法；然而，滑膜肉瘤仍然是一种预后不良的高级别肉瘤，目前正在开发新的抗癌药物和免疫治疗方法。患者来源的细胞系是基础和临床前研究的重要工具。然而，细胞库中只有少数患者来源的滑膜肉瘤细胞系可供公开使用。因此，本研究旨在建立和鉴定一种新型滑膜肉瘤细胞系。我们使用一名 48 岁女性患者的手术切除肿瘤组织成功建立了一个细胞系，命名为 NCC-SS3-C1。NCC-SS3-C1 细胞携带 SS18-SSX1 融合基因，表现出中等程度的生长、球体形成和侵袭能力。我们使用 NCC-SS3-C1 细胞检测了一系列小分子抗癌化合物的增殖抑制作用，包括 FDA 批准的抗癌药物，并确定了抑制 NCC-SS3-C1 细胞增殖的抗癌药物在低浓度下。我们得出结论，NCC-SS3-C1 将成为基础和临床前滑膜肉瘤研究的有用工具。
